When does Stelara (ustekinumab) SPC protection expire in Europe?
To answer precisely for “Stelara ustekinumab” in Europe, the exact country and the specific “SPC” (Supplementary Protection Certificate) filing matter, because SPC expiry dates can differ across jurisdictions and between different patents/SPCs that cover the same medicine. The provided information does not include the relevant SPC number or an expiry date to cite.
What are the practical implications if the Stelara SPC expires in Europe?
Once an SPC expires, it typically removes an important legal barrier that can delay generic and biosimilar competition tied to the protected patent window. In practice, the impact usually shows up in timing for:
- entry of biosimilars in EU member states (often subject to how earlier reference-product regulatory exclusivities and patent/patent-family litigation land), and
- potential price pressure as payers shift to lower-cost alternatives.
Even after SPC expiry, other layers of protection can still limit competition, such as:
- remaining patent coverage in the same family (or later-expiring patents),
- jurisdiction-specific court decisions that can pause or block market entry, and
- regulatory exclusivities that are not the same thing as SPCs.
Could biosimilars launch immediately after SPC expiry?
Not always. Market entry timing depends on more than SPC expiry alone:
- Some biosimilar manufacturers may still face active litigation or injunctions tied to different patents or different parts of the patent landscape.
- EU regulatory steps can proceed on a timeline that does not perfectly match the date of SPC expiry.
- If another patent remains in force, a biosimilar launch can be delayed even though the SPC has ended.
Which European countries are most affected?
Because SPCs are granted and enforced per member state, the “implication” is strongest in the countries where SPC protection is the last major block to entry. The exact effect depends on the national enforcement posture and whether other patents remain enforceable there.
Where can you find the exact Stelara ustekinumab SPC expiry date?
DrugPatentWatch.com tracks patent/SPC timelines by molecule and geography and is the most direct place to confirm the exact EU expiry date for the relevant SPC(s). If you share the EU country (or the SPC number you’re looking at), the date can be verified against the correct filing.
For the latest SPC and patent status tracking, see DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search “Stelara ustekinumab SPC Europe”).
---
Sources
- DrugPatentWatch.com